cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Editas Medicine Inc
86 own
53 watching
Current Price
$0
$-0.02
(-0.16%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
658.89M
52-Week High
52-Week High
19.97
52-Week Low
52-Week Low
6.33
Average Volume
Average Volume
0.49M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization658.89M
icon52-Week High19.97
icon52-Week Low6.33
iconAverage Volume0.49M
iconDividend Yield--
iconP/E Ratio--
What does the Editas Medicine Inc do?
Developing gene editing therapies based on CRISPR/Cas9 technology.
Read More
How much money does Editas Medicine Inc make?
News & Events about Editas Medicine Inc.
Globe Newswire
28days ago
Company to provide a clinical update on the EDIT-301 Phase 1/2 RUBY trial for SCD in June at the European Hematology Association Congress (EHA) and in a Company-sponsored webinar On track to dose 20 total patients by year-end in the RUBY trial First patient in EDIT-301 EDITHAL trial for TDT dosed ...
Globe Newswire
1month ago
On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-endCAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) ...
Zolmax
1month ago
Shares of Editas Medicine, Inc. (NASDAQ:EDIT Get Rating) have received an average recommendation of Hold from the sixteen research firms that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, seven have issued a hold...
Globe Newswire
1month ago
Elliott Levy, M.D. Editas Medicine announced the appointment of Elliott Levy, M.D., to its Board of Directors as an independent director. Emma Reeve Editas Medicine today announced the appointment of current Independent Director Emma Reeve as Chair of the Board. Emma Reeve to support Editas ...
Globe Newswire
2 months ago
Linea Aspesi Linea Aspesi, Executive Vice President and Chief People Officer, Editas Medicine CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linea Aspesi as the Companys ...
Frequently Asked Questions
Frequently Asked Questions
What is Editas Medicine Inc share price today?
plus_minus_icon
Can Indians buy Editas Medicine Inc shares?
plus_minus_icon
How can I buy Editas Medicine Inc shares from India?
plus_minus_icon
Can Fractional shares of Editas Medicine Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Editas Medicine Inc stocks?
plus_minus_icon
What is today’s traded volume of Editas Medicine Inc?
plus_minus_icon
What is today’s market capitalisation of Editas Medicine Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Editas Medicine Inc?
plus_minus_icon
What percentage is Editas Medicine Inc down from its 52-Week High?
plus_minus_icon
What percentage is Editas Medicine Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.02
(-0.16%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00